Abstract
The α1-adrenoceptor-antagonistic and steroid 5α–reductase-inhibitory actions of Z-350 [(S)-4-{3-{4-{1-(4-methylphenyl)-3-[4-(2-methoxyphenyl)piperazine-1-yl]propoxy}benzoyl}indole-1-yl}butyric acid hydrochloride] were investigated in rabbits and rats in vivo. Z-350 (1–30 mg/kg), administered intraduodenally, dose-dependently inhibited phenylephrine-induced increases in prostatic urethral pressure with an ED50 value of 3.8 mg/kg in anesthetized male rabbits, whereas the effects on mean blood pressure and orthostatic hypotensive response were weaker when compared with other α1-adrenoceptor antagonists, tamsulosin and prazosin. Z-350 (1–10 mg/kg p.o.) dose-dependently inhibited the prostatic steroid 5α-reductase activity in rats with an ED50 value of 2.8 mg/kg. The daily oral administration of Z-350, at ≧10 mg/kg for 7 days, significantly reduced the prostatic growth induced by testosterone in castrated rats, with no effect on dihydrotestosterone-induced prostatic growth. These results indicate that Z-350 exhibited α1-adrenoceptor-antagonistic and 5α-reductase inhibitory actions at almost equal doses in vivo, and was expected to improve the bladder outlet obstruction associated with benign prostatic hyperplasia with smaller cardiovascular adverse effect.
Footnotes
-
Send reprint requests to: Yoshihisa Fukuta, Central Research Laboratories, Zeria Pharmaceutical Co., Ltd. 2512–1, Oshikiri, Kohnan-machi, Ohsato-gun, Saitama 360-0111, Japan.
- Abbreviations:
- BPH
- benign prostatic hyperplasia
- UP
- prostatic urethral pressure
- MBP
- mean blood pressure
- OI
- orthostatic index
- DHT
- dihydrotestosterone
- Z-350
- (S)-4-{3-{4-{1-(4-methylphenyl)-3-[4-(2-methoxyphenyl)piperazine-1-yl]propoxy}benzoyl}indole-1-yl}butyric acid hydrochloride
- Received January 27, 1999.
- Accepted May 6, 1999.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|